

Synthesis and trypanocidal activity of *ent*-kaurane glycosides

Ronan Batista,^{a,b} Jorge Luiz Humberto,^c Egler Chiari^d and Alaíde Braga de Oliveira^{b,*}

^a*Departamento de Estudos Básicos e Instrumentais, Universidade Estadual do Sudoeste da Bahia,
BR 415, km 03, CEP 45.700-000, Itapetinga, BA, Brazil*

^b*Faculdade de Farmácia, Departamento de Produtos Farmacêuticos, Universidade Federal de Minas Gerais,
Av. Antônio Carlos, 6.627, CEP 31.270-901, Belo Horizonte, MG, Brazil*

^c*Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Morro do Cruzeiro, sln^o,
Bauxita, 35.400-000, Ouro Preto, MG, Brazil*

^d*Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais,
Av. Antônio Carlos, 6.627, CEP 31.270-901, Belo Horizonte, MG, Brazil*

Received 20 August 2006; revised 21 September 2006; accepted 22 September 2006

Available online 20 October 2006

Abstract—Novel *ent*-kaurane glucosides were synthesized by a Koenigs–Knorr reaction between C17 and C19 alcohols derived from kaurenoic acid and 2,3,4,6-tetra-*O*-acetyl-glucopyranosyl bromide, followed by the hydrolysis of the acetates. Main products were assayed *in vitro* and *in vivo* against blood trypomastigote forms of *Trypanosoma cruzi*, the aetiological agent of Chagas' disease (American trypanosomiasis). The results allowed to establish structure–activity relationships among these derivatives, as well as pointed out the C19-methylester-C17-*O*-glucoside as a potential trypanocidal agent, whose trypanocidal profile was shown to be comparable to those of gentian violet and benznidazole.

© 2006 Elsevier Ltd. All rights reserved.

1. Introduction

Chagas' disease (American trypanosomiasis) belongs to the group of the so-called Drug Neglected Diseases—DND, and is one of the most neglected tropical endemics.¹ Of the 1223 new drugs (new chemical entities) which entered the market between 1975 and 1996, only two were for Chagas' disease therapy: benznidazole, a nitroimidazole derivative (Rochagan[®], Roche) and nifurtimox, a nitrofurant derivative (Lampit[®], Bayer). Both drugs have significant activity in the acute phase, with about 80% of parasitological cures in treated patients, but their very low antiparasitic effect in chronic patients remains major limitation to their clinical use.^{1,2}

Trypanosoma cruzi, a haemoflagellate protozoan (family Trypanosomatidae, order Kinetoplastida), is the aetiological agent of Chagas' disease and its life cycle

involves obligatory passage through vertebrate (mammals, including human) and invertebrate (hematophagous triatomine bugs) hosts. Transmission of the infective trypomastigote form occurs mainly by vector insect bite (80–90%), blood transfusion (5–20%) and congenital routes (0.5–8.0%). The chronic disease is characterized by cardiac, digestive or neurological disturbances.²

Control of vectorial and transfusion transmissions has been successfully carried out in Brazil. However, 16–20 million people in Latin America are infected with *T. cruzi* causing 21,000 deaths and 200,000 new infections annually in 15 countries (from Mexico to Argentina). The incidence of this infection afflicts >80% of the population in some regions of Bolivia and Mexico.³ Intense migration of people from endemic Latin American countries must be cause of concern for USA health authorities as it was recorded that between 50,000 and 100,000 people are infected per year in this country.⁴

Gentian violet is recommended for sterilization of blood stored in blood banks of endemic regions, but despite its effectiveness, there are some restrictions to its use due to

Keywords: Kaurenoic acid; *ent*-Kaurane glycosides; Koenigs–Knorr reaction; *Trypanosoma cruzi*.

* Corresponding author. Tel./fax: +55 31 3441 5575; e-mail: alaidebraga@terra.com.br

side effects.⁵ New and safer trypanocidal compounds are needed both for prophylaxis and therapy. It is recommended that the search for prophylactic drugs as alternatives to gentian violet must initially involve *in vitro* assays with trypomastigotes in the presence of blood at 4 °C. Besides being colourless and soluble in the aqueous medium, the compounds should not be inactivated by blood elements or be toxic to them. Many trypanocidal compounds, including available drugs of several therapeutic classes, have been identified, but no one currently can be used as a substitute for gentian violet.² An 8-aminoquinoline compound (WR6026) seems to be the most promising candidate to prevent transfusion associated Chagas' disease.^{6,7}

The *in vitro* assay with *T. cruzi* trypomastigotes could also lead to the identification of potential drugs for Chagas' disease chemotherapy. The *in vitro* active compounds should be further evaluated for *in vivo* sensitivity in mice experimentally infected with *T. cruzi*. In a rapid test, the suppressive effect on parasitaemia occurs almost immediately after administration of an effective drug⁸ and this assay would allow the selection of candidates for curative murine models of acute or chronic Chagas' disease. A limitation to the evaluation of natural products is the amount of sample required for the *in vivo* assays, about 20 mg for the rapid test (6 h) and 500 mg for a 20-day treatment. Therefore, *in vivo* assays of natural products are restricted to abundant ones.

Widely occurring and sometimes abundant triterpene and diterpene acids, like ursolic and kaurenoic acids, have been shown to be active in the *in vitro* assays against the blood trypomastigote form of *T. cruzi*.^{9–14} Kaurenoic acid, a diterpene commonly isolated from some Asteraceae and Annonaceae species, caused not only complete elimination of trypomastigotes from the blood in the *in vitro* assays at high concentrations (>1 mM), but also complete lysis of erythrocytes^{11,15}, although this haemolytic effect had not been reported previously.⁹ Besides, it is insoluble in aqueous medium and cannot be used as a prophylactic agent unless a hydrosoluble derivative could be obtained.

Kaurenoic acid is abundant in some Brazilian plant species belonging to the genera *Xylopia* (Annonaceae), *Mikania* and *Wedelia* (Asteraceae), the highest content being found for *X. frutescens* seeds (ca. 3%).¹⁶ It has been used as starting material for chemical synthesis aiming to improve its trypanocidal activity. A series of amides, amines and amine hydrochlorides was obtained by reactions on the carboxyl group. Aqueous solubility of the amine salts did not improve the trypanocidal activity level in relation to kaurenoic acid, although a decrease of haemolysis was observed.¹⁵


The potentiality of the abundant kaurenoic acid for synthetic modifications is far from being completely exploited. In the present paper, we report the synthesis of glycosides derived from this diterpene acid and their evaluation as trypanocidal agents.

2. Results and discussion


2.1. Chemistry

Our synthetic approach involved the conversion of kaurenoic acid (**1**) into the alcohols **3** and **4** that were submitted to glycosidation (Scheme 1). The methyl ester **2** and the alcohols **3** and **4** were obtained according to usual procedures: esterification with diazomethane, followed by LiAlH₄ reduction (**3**)¹⁵ or hydroboration–oxidation (**4**). The *ent*-16 α configuration of **4** was unambiguously assigned previously.¹⁷

Glycosidation of **3** by the classic Koenigs–Knorr reaction^{18,19} (Scheme 2) was carried on with 2,3,4,6-tetra-*O*-acetyl-glucopyranosyl bromide (**5**), in the presence of Hg(CN)₂, in toluene, at ca. 80 °C (80 h), and required a long time (140 h), affording the alcohol acetate **7** as major product (50% isolated yield) and a mixture (1:1) of the peracetylated β -glycosides **8a/b** (34% yield) that, under hydrolysis with sodium methoxide, gave a mixture (1:1) of the β -glucosides **10a/b** whose separation could not be achieved. The β -configuration of the anomeric carbons in **8a/b** and **10a/b** was indicated by the H-1' coupling constants (**8a/b**, δ 4.41, d, J = 7.8 Hz; **10a/b**, δ 4.18,



Scheme 1. Synthesis of the kaurane alcohols **3** and **4**. Reagents and conditions: (a) CH₂N₂, Et₂O, 4 h; (b) LiAlH₄, THF, reflux, 3 h; (c) NaBH₄, BF₃·OEt₂, THF, 2 h; (d) NaOH, H₂O₂, 1 h.



Scheme 2. Synthesis of the kaurane derivatives **6–10a/b** from the alcohol **3**. (a) $\text{C}_6\text{H}_5\text{Me}$, (**5**), $\text{Hg}(\text{CN})_2$, rt (24 h), 80°C , 66 h; (b) $\text{C}_6\text{H}_5\text{Me}$, (**5**), $\text{Hg}(\text{CN})_2$, 80°C , 140 h; (c) $\text{MeOH}/\text{H}_2\text{O}/\text{Et}_3\text{N}$ (8:1:1), rt, 24 h; (d) MeO^-Na^+ , MeOH , rt, 4 h.

d, $J = 7.6$ Hz) and signals for C-1' at δ 101.7 (**8a/b**) and δ 105.2 (**10a/b**).

Glycosidation of **4** (Scheme 3), in similar conditions used for **3** [$\text{Hg}(\text{CN})_2$, toluene, 80°C], gave the α -peracetylated glucoside **13** (37% yield) and the acetate derivative **14** (25% yield). The α -glucoside **16** was obtained in 81% yield after hydrolysis of **13** with sodium methoxide. Reductive de-*O*-acetylation of **13** with LiAlH_4 afforded the α -glucoside alcohol **15** in 68% isolated yield (Scheme 3). ^1H NMR spectra of **13**, **15** and **16** exhibited a one proton doublet at δ 5.08 ($J = 3.7$ Hz), 4.77 ($J = 3.8$ Hz) and 4.77 ($J = 3.8$ Hz), respectively, and are consistent with α -anomeric glycosides. Characteristic chemical shifts of C-1' anomeric carbons were observed in ^{13}C NMR spectra of **13** (δ 96.2), **15** (δ 100.4) and **16** (δ 100.4).


Attempts to obtain higher yields in the glycosidation of the alcohols **3** and **4** were carried on by keeping the Koenigs–Knorr reaction at room temperature for 24 h and then heating to 80°C until the disappearance of the starting materials in TLC. These procedures led to the orthoester **6** (44%) and the alcohol acetate **7** (25%) (Scheme 2), as well as to the orthoester **11** (54%) and

the glucoside **12** (37%) (Scheme 3). Hydrolysis of **6** with $\text{MeOH}/\text{H}_2\text{O}/\text{Et}_3\text{N}$ (8:1:1) gave the α -2-*O*-acetylglucoside **9** (73% yield). ^1H and ^{13}C NMR spectra showed characteristic signals for H-1' (δ 5.66, d, $J = 5.2$ Hz), C-1' (δ 96.8) and C-7' (δ 121.5) of the orthoester **6**, and for the anomeric H-1' (δ 6.10, d, $J = 3.6$ Hz) and C-1' (δ 93.6) of **9**.

The alcohol acetates **7** and **14** are indicative of the formation of the respective orthoesters what very often occurs in the classic Koenigs–Knorr glycosidation procedure and involves the participation of the carbonyl group at C-2' of the glycosylating agent. Formation of these products is favoured when the acceptor alcohol is sterically hindered²⁰ what indeed explains a higher yield of **7** (50%) than **14** (25%). ^1H and ^{13}C NMR data for compounds **1–16** are found in Tables 1 and 2.

2.2. Trypanocidal activity

Aiming to evaluate the preliminary trypanocidal activity of the main compounds of this work, in order to select the most potential active ones for the next *in vivo* assay, an *in vitro* evaluation of compounds **1–4**, **9**, **10a/b**, **15** and **16** against trypomastigotes of *T. cruzi* (Y strain)



Scheme 3. Synthesis of the kaurane derivatives **11–16** from the alcohol **4**. Reagents and conditions: (a) $\text{C}_6\text{H}_5\text{Me}$, (**5**), $\text{Hg}(\text{CN})_2$, rt, 24 h, 60 °C, 48 h, 80 °C, 24 h; (b) $\text{C}_6\text{H}_5\text{Me}$, (**5**), $\text{Hg}(\text{CN})_2$, 70 °C, 72 h; (c) LiAlH_4 , THF, rt, 1 h; (d) MeO^-Na^+ , MeOH, 4 h.

was performed according to methodology previously described,^{11,17,21,22} and the results are shown in Table 3.

Compounds **1**, **2** and **4** disclosed the expected profile, causing complete (**1** and **4**) or almost complete (**2**) elimination of parasites, besides lysis of erythrocytes (**1** and **4**), at concentrations higher than 1 mM, the haemolytic effect being stronger (total lysis) for kaurenoic acid (**1**) than for the methyl ester alcohol derivative **4** (partial lysis) and the methyl ester **2** (absence of lysis). Kaurene alcohol **3** was less active, complete elimination of parasites occurring only at 5.00 mM without significant haemolysis. It seems that the haemolytic effect is related to the presence of a carboxylic acid group at C19. For glucosides **9**, **10a/b** and **15**, in comparison with the respective aglycones **3** and **4**, a decrease in the trypanocidal effect was observed. On the other hand, the C19-methylester-C17-*O*-glucoside **16** was more active than kaurenoic acid (**1**) and the corresponding alcohol **4**, with the advantage of causing no significant haemolysis, what

is a desirable characteristic for a Chagas' disease chemoprophylactic agent. Other favourable properties of **16**, as a potential trypanocidal agent to be added to transfusional blood, are its colourless and better solubility in aqueous media. Besides, the trypanocidal profile of **16** is very close to the one observed for gentian violet, the standard chemoprophylactic drug, at least in the conditions of the *in vitro* assays.

Based on the results depicted in Table 3, and considering the amount of each compound available, compounds **2** (kaurenoic acid methyl ester) and **16** (C19-methylester-C17-*O*-glucoside) were assayed to determine the sensitivity of *T. cruzi* *in vivo* within a short period of time (6 h). A rapid method detecting activity against trypomastigotes circulating blood forms was used for assessment. This method is based on the fact that *T. cruzi* blood forms intravenously inoculated into mice persist for some hours in the bloodstream without penetrating the host tissues whereas with active drugs

Table 1. ¹H NMR data [δ ppm, J Hz, CDCl₃] data for compounds **1–16**

H	1	2	3	4	5	6	7	8a	8b	
13	2.64 br s	2.64 br s	2.63 br s	2.13 br s	—	2.64 br s	2.64 br s	2.64 br s	2.32 br s	
15a/b	2.05 m	2.05 m	2.05 m	2.2–0.7 m	—	2.04 m	2.04 m	1.98 m	5.04 s	
16	—	—	—	2.28 m	—	—	—	—	—	
17a	4.79 br s	4.79 br s	4.79 br s	} 3.70 d (6.9)	—	4.79 br s	4.79 br s	4.79 br s	} 1.69 d (1.3)	
17b	4.73 br s	4.74 br s	4.73 br s		—	4.73 br s	4.73 br s	4.73 br s		
18	1.24 s	1.17 s	0.96 s	1.16 s	—	0.90 s	0.94 s	0.89 s	0.89 s	
19a	—	—	3.74 d (10.9)	—	—	3.59 d (11.0)	4.22 d (11.0)	3.95 td (3.0; 9.3)	3.95 td (3.0; 9.3)	
19b	—	—	3.43 d (10.9)	—	—	3.20 d (11.0)	3.87 d (11.0)	3.18 d (9.3)	3.18 d (9.3)	
20	0.95 s	0.83 s	1.01 s	0.81 s	—	1.01 s	1.03 s	1.01 s	1.01 s	
21	—	3.64 s	—	3.64 s	—	—	—	—	—	
1'	—	—	—	—	6.61 d (4.0)	5.66 d (5.2)	—	4.41 d (7.8)	4.41 d (7.8)	
2'	—	—	—	—	4.84 dd (4.0; 10.0)	4.30 dd (3.1; 5.1)	—	5.20 t (9.3)	5.20 t (9.3)	
3'	—	—	—	—	5.56 t (9.7)	5.19 t (2.9)	—	} 4.96–5.12 m	} 4.96–5.12 m	
4'	—	—	—	—	5.16 t (9.7)	4.90 dd (2.7; 9.5)	—			
5'	—	—	—	—	} 4.38–4.25 m	} 3.95 ddd (3.6; 4.5; 5.4)	—	} 3.68 ddd (2.5; 4.8; 9.5)	} 3.68 ddd (2.5; 4.8; 9.5)	
6'a	—	—	—	—			4.21 s			—
6'b	—	—	—	—	4.12 dd (3.4; 13.0)	4.20 d (1.6)	—	4.12 dd (2.5; 12.1)	4.12 dd (2.5; 12.1)	
8'	—	—	—	—	—	1.70 s	—	—	—	
CH ₃ CO	—	—	—	—	2.04 s	2.09 s	2.05 s	2.01 s	2.01 s	
					2.06 s	2.10 s	—	2.03 s	2.03 s	
					2.10 s	2.12 s	—	2.04 s	2.04 s	
					2.11 s	—	—	2.09 s	2.09 s	
H	9 ^a	10a ^a	10b ^a	11	12	13	14	15 ^a	16 ^a	
13	2.61 br s	2.61 br s	2.28 br s	2.19 m	2.16 br d (13.0)	2.14 m	2.15 m	2.19 br s	2.18 br s	
15a/b	2.04 m	2.05 m	5.03 s	2.2–0.8 m	2.1–0.8 m	2.1–0.7 m	2.2–0.7 m	1.7–0.7 m	1.9–1.0 m	
16	—	—	—	2.19 m	2.22 m	2.27 m	2.28 m	2.30 m	2.33 m	
17a	4.77 br s	4.78 br s	} 1.68 d (1.3)	3.71 t (7.3)	3.95 dd (7.5; 9.6)	3.76 dd (7.5; 9.4)	4.19 dd (8.0; 10.8)	3.82 t (8.4)	3.83 dd (8.4; 9.4)	
17b	4.71 br s	4.71 br s		3.54 dd (3.9; 7.7)	3.55 dd (8.0; 9.6)	3.46 dd (8.6; 9.2)	4.09 dd (8.0; 10.8)	3.52 dd (7.2; 9.5)	3.53 dd (7.2; 9.6)	
18	0.93 s	1.00 s	1.00 s	1.16 s	1.16 s	1.16 s	1.16 s	0.93s	1.16 s	
19a	} 3.90–3.10 m	4.08 dd (2.2; 9.6)	4.08 dd (2.2; 9.6)	—	—	—	—	3.70 d (10.9)	—	
19b		3.40–3.10 m	3.40–3.10 m	—	—	—	—	3.33–3.30 m	—	
20	1.04 s	1.07 s	1.07 s	0.81 s	0.81 s	0.81 s	0.81 s	1.03 s	0.85 s	
21	—	—	—	3.63 s	3.64 s	3.64 s	3.64 s	—	3.63 s	
1'	6.10 d (3.6)	4.18 t (7.6)	4.18 t (7.6)	5.69 d (5.2)	4.52 d (8.0)	5.08 d (3.7)	—	4.77 d (3.8)	4.77 d (3.8)	
2'	3.54 dd (3.6; 9.5)	} 3.40–3.10 m	} 3.40–3.10 m	4.31 dd (4.0; 5.1)	4.97 dd (8.0; 9.5)	4.83 dd (3.8; 10.2)	—	3.37 dd (3.8; 9.7)	3.38 dd (3.8; 9.7)	
3'	} 3.90–3.10m			} 3.40–3.10m	5.19 t (2.8)	5.20 t (9.5)	5.46 t (9.8)	—	3.69–3.55 m	3.69–3.60 m
4'					4.90 dd (2.6; 10.2)	5.08 t (9.6)	5.03 t (9.8)	—	3.27 t (9.6)	3.27 t (9.7)
5'					3.95 m	3.68 m	4.03 m	—	3.69–3.55 m	3.69–3.60 m
6'a	} 3.90–3.10m	3.86 dd (2.1; 11.8)	3.86 dd (2.1; 11.8)	} 4.20 d (4.4)	4.26 dd (4.5; 12.0)	4.24 dd (4.8; 12.3)	—	3.80 dd (2.2; 11.6)	3.80 dd (2.2; 11.4)	
6'b		3.68 dd (4.9; 11.8)	3.68 dd (4.9; 11.8)		4.14 dd (2.5; 12.5)	4.10 dd (2.3; 12.3)	—	3.69–3.55 m	3.69–3.60 m	
8'	—	—	—	1.73 s	—	—	—	—	—	
CH ₃ CO	2.12 s	—	—	2.09 s	2.00 s	2.01 s	2.04 s	—	—	
				2.10 s	2.02 s	2.03 s				
				2.12 s	2.03 s	2.04 s				
					2.08 s	2.09 s				

^a CD₃OD.

Table 2. ^{13}C NMR data (δ ppm, CDCl_3) for compounds **1–16**

C	1	2	3	4	5	6	7	8a	8b
1	40.7	40.8	40.5	40.8	—	40.4	40.4	39.7	39.9
2	19.1	19.1	18.3	19.2	—	18.3	18.3	18.2	18.2
3	37.7	38.1	35.6	38.1	—	36.1	36.4	36.3	36.3
4	43.2	43.8	38.7	43.7	—	37.4	37.1	37.8	37.8
5	57.1	57.1	56.9	57.0	—	56.8	56.9	56.6	56.3
6	21.8	21.9	20.5	22.3	—	20.5	20.5	20.8	20.5
7	41.3	41.3	41.6	42.1	—	41.6	41.6	41.6	44.0
8	44.2	44.2	44.2	44.2	—	44.2	44.2	44.2	49.2
9	55.1	55.1	56.2	56.4	—	56.2	56.2	56.2	49.1
10	39.7	39.4	39.2	39.5	—	39.2	39.2	39.2	39.4
11	18.4	18.4	18.2	19.2	—	18.2	18.2	18.7	19.6
12	33.1	33.1	33.2	26.0	—	33.2	33.2	33.2	25.0
13	43.8	43.8	44.0	37.0	—	44.0	44.0	43.8	44.9
14	39.7	39.7	39.7	40.4	—	39.7	39.7	40.5	40.4
15	48.9	48.9	49.1	43.8	—	49.1	49.1	49.0	135.4
16	155.9	155.9	155.8	43.3	—	155.8	155.8	155.8	142.5
17	103.0	102.9	103.0	64.2	—	103.0	103.0	103.0	15.4
18	29.0	28.7	27.1	28.7	—	27.8	27.6	27.4	27.5
19	184.8	178.1	65.6	178.2	—	65.9	67.2	73.7	73.7
20	15.6	15.4	18.1	15.4	—	18.2	18.1	18.2	18.1
21	—	51.1	—	51.1	—	—	—	—	—
1'	—	—	—	—	86.6	96.8	—	101.7	101.7
2'	—	—	—	—	70.1	73.3	—	73.3	73.3
3'	—	—	—	—	72.1	70.3	—	72.0	72.0
4'	—	—	—	—	67.2	68.2	—	71.7	71.7
5'	—	—	—	—	70.6	67.0	—	69.1	69.1
6'	—	—	—	—	61.0	63.1	—	62.1	62.1
7'	—	—	—	—	—	121.5	—	—	—
8'	—	—	—	—	—	20.7	—	—	—
—COCH ₃	—	—	—	—	20.5	20.8	21.1	20.6	20.6
	—	—	—	—	20.6	20.8	—	20.6	20.6
	—	—	—	—	20.6	20.9	—	20.7	20.7
	—	—	—	—	20.7	—	—	20.8	20.8
—COCH ₃	—	—	—	—	169.5	169.2	171.4	169.2	169.2
	—	—	—	—	169.8	169.7	—	169.4	169.4
	—	—	—	—	169.9	170.7	—	170.4	170.4
	—	—	—	—	170.5	—	—	170.7	170.7
C	9*	10a*	10b*	11	12	13	14	15*	16*
1	40.9	40.9	40.9	40.2	40.8	41.1	40.9	41.6	41.6
2	19.5	19.6	19.6	19.1	19.2	19.6	19.3	20.2	20.4
3	36.8	37.6	37.6	38.0	38.1	38.5	38.3	36.9	39.3
4	39.9	39.3	39.3	43.7	43.8	44.2	44.0	39.9	45.2
5	58.4	58.5	58.2	56.9	57.0	57.4	57.2	59.2	58.4
6	21.5	21.7	20.7	22.2	22.2	22.6	22.4	21.9	23.5
7	43.0	43.1	45.0	42.0	42.1	42.4	42.2	44.0	43.4
8	45.5	45.5	50.6	44.1	44.3	44.7	44.5	45.7	45.6
9	57.9	57.9	50.8	56.3	56.5	56.8	56.5	58.5	58.0
10	40.6	40.6	40.8	39.3	39.5	39.8	39.6	40.6	40.8
11	19.4	19.4	20.0	19.1	19.1	19.5	19.2	19.5	20.4
12	34.4	34.4	26.2	25.8	25.9	26.3	26.2	27.4	27.4
13	45.5	45.5	46.4	37.1	37.3	37.6	37.5	39.3	39.1
14	41.9	41.9	41.4	40.7	39.8	40.6	40.5	42.0	42.1
15	50.4	50.4	136.8	43.8	44.0	44.2	43.9	46.1	45.8
16	156.9	157.0	143.5	40.0	40.3	40.2	39.3	41.5	41.6
17	103.8	103.8	15.6	64.9	71.6	70.3	66.2	71.1	71.1
18	28.0	28.5	28.6	28.7	28.7	29.1	28.9	28.0	29.3
19	65.3	73.9	74.0	178.0	178.0	178.4	178.3	65.3	179.9
20	19.0	19.0	18.9	15.3	15.4	15.7	15.6	19.1	16.2
21	—	—	—	51.0	51.1	51.1	51.3	—	51.8
1'	93.6	105.2	105.2	96.8	100.8	96.2	—	100.4	100.4
2'	72.4	75.4	75.4	73.0	72.9	71.4	—	73.9	73.9
3'	76.1	78.4	78.4	70.1	71.8	70.3	—	73.8	73.8
4'	71.2	71.8	71.8	68.2	71.4	69.1	—	72.1	72.1
5'	74.9	77.9	77.9	66.9	68.5	67.5	—	75.0	75.3

Table 2 (continued)

C	9*	10a*	10b*	11	12	13	14	15*	16*
6'	62.4	62.9	62.9	63.1	62.1	62.5	—	63.0	62.9
7'	21.1	—	—	121.2	—	—	—	—	—
8'	171.8	—	—	20.8	—	—	—	—	—
—COCH ₃	—	—	—	20.6	20.6	21.0	21.3	—	—
				20.7	20.6	21.0	—		
				20.8	20.7	21.1	—		
				—	20.7	21.1	—		
—COCH ₃				169.1	169.2	170.0	171.6		
				169.6	169.4	170.5	—		
				170.6	170.3	170.6	—		
				—	170.7	171.0	—		

Table 3. Results of the *in vitro* assays of compounds 1–4, 9, 10a/b, 15, 16 and gentian violet against bloodstream trypomastigotes of *Trypanosoma cruzi* Y strain

Compound	Concentrations (mM) × % parasite lysis				
	0.31	0.63	1.25	2.50	5.00
1	0	90 (H)	100 (TH)	100 (TH)	100 (TH)
2	45	48	88	100	100
4	45	94 (H)	100 (H)	100 (H)	100 (H)
3	NT	NT	66	72	100
9	NT	NT	0	0	56
10a/b	NT	NT	0	0	36
15	NT	NT	0	38	55
16	51	96	100	100	100
NC	0	0	0	0	0
Gentian violet	67	100	100	100	NT

NC, negative control (1% DMSO + TCM199); NT, not tested; H, partial haemolysis; TH, total haemolysis.

a rapid decline in the number of blood parasites is observed.⁸ Swiss male albino mice (18–20 g) were intra-peritoneally inoculated with blood trypomastigotes of *T. cruzi* Y strain and, at the peak of parasitaemia (7th day), a single dose of 250 mg/kg of the compounds was given by oral route. The number of circulating bloodstream forms was microscopically determined, before injection and 4 and 6 h later. Untreated mice similarly inoculated were used as negative controls and benznidazole (Rochagan®, Roche) at a dose of 250 mg/kg served as positive control. Groups of three mice were used in all experiments. The results are shown in Table 4. Parasitaemia reductions determined with benznidazole (4 h $91.7 \pm 3.9\%$; 6 h $92.6 \pm 3.5\%$) and for untreated mice (4 h $29.6 \pm 10.5\%$; 6 h $23.3 \pm 11.9\%$) showed statistically significant difference and are clearly

indicative of positive and negative control, respectively. For compounds 2 and 16 parasitaemia reductions were significantly higher than those of the negative control both at 4 and 6 h and for each compound the parasitaemias were equivalent after 4 and 6 h. Moreover, at 4 h, there was no significant reduction in parasitaemia between mice treated with 16 and the group of the standard drug benznidazole (positive control). Thus, both these *ent*-kaurane derivatives have shown *in vivo* trypanocidal activity. The result for 16 is remarkable for the observed equivalence with benznidazole after 4 h of administration. On the other hand, its effect significantly decreases after 6 h while the one of benznidazole is maintained at the same level. This might be explained by the possible hydrolysis of the ester and/or glycosidic functions.

Table 4. Results of *in vivo* assays of compounds 2 and 16 in mice in the acute phase of *Trypanosoma cruzi* infection by the rapid method⁸

Compounds	Parasitaemia reductions (%) (means ± SD*)	
	T = 4 h	T = 6 h
NC	29.6 ± 10.5 ^{aA}	23.3 ± 11.9 ^{bA}
2	56.5 ± 18.2 ^{aB}	51.5 ± 13.3 ^{bB}
16	70.3 ± 13.3 ^{aBC}	68.0 ± 10.5 ^{aB}
PC (Benznidazole)	91.7 ± 3.9 ^{aC}	92.6 ± 3.5 ^{aC}

NC, negative control (1% DMSO + TCM199); PC, positive control; T, time in hours after administration to mice, in the 7th day after inoculation with trypomastigotes of *T. cruzi* Y strain. a, b—comparison in the same line. A, B, C—comparison in the same column.

* $P < 0.05$.

The results of the *in vitro* assays for **15** and **16** (Table 3) indicate that an ester group at C19 makes a significant contribution to the trypanocidal activity that decreases for C19-alcohols (**3** and **15**) and C19-*O*-glucosides (**10a/b**). The double bond between C16 and C17 is not essential for the activity, since the trypanocidal effect is increased after its hydroxylation, as can be deduced by comparing the effects of **2** and **4** (Table 3). Considering the *in vitro* profile of compounds **4** and **16**, one can conclude that glycosidation of **4** does not affect the trypanocidal activity, but the undesirable haemolytic effect is suppressed. Moreover, the good profile of **16** in the *in vitro* and *in vivo* assays might be attributed to more favourable pharmacokinetic properties since the glycosyl moiety attached to the kaurane skeleton must increase its hydrophilicity and influence the transport through the cell membrane.²³ For this reason, the present results support the quest for more polar derivatives of kaurenoic acid.

In addition, it should be pointed out that the utility of the rapid *in vivo* method as a screening technique permits the evaluation of the trypanocidal activity in a short period of time (6 h) only requiring a small number of test animals. Besides, as it has been originally described by Filardi & Brener,⁸ this method shows a fairly good correlation with those obtained by prolonged treatment schedules used to assess the action of drugs in experimental Chagas' disease.⁸ Thus, compounds **2** and **16** can be considered promising chemotherapeutic agents deserving further evaluations.

3. Experimental

3.1. Chemistry

Melting points were taken with a Microquímica apparatus APF-301 and uncorrected. Optical rotations were measured with a Bellinghan & Stanley P20 polarimeter. IR spectra were obtained on a Perkin-Elmer FT-IR spectrophotometer in diamond film. NMR spectra were recorded at 400 MHz for ¹H and 100 MHz for ¹³C in deuteriochloroform or deuteromethanol, added of TMS as internal reference, on a Bruker DRX 400. Chemical shift values are expressed in ppm and coupling constants (*J*) in Hz. Column chromatography (CC) and flash column chromatography (FCC) were performed on silica gel Merck 60 (0.063–0.200 and 0.040–0.063 mm, respectively). HRMS were run in a VG TS-250 spectrometer working at 70 eV. TLC were carried out on silica gel Merck 60 F₂₅₄ (0.25 mm thick). Solvents and reagents were purified by standard procedures.

3.1.1. ent-Kaur-16-en-19-oic acid (kaurenoic acid) (1). It was obtained from *Wedelia paludosa* ethanol extract, as described previously.¹¹

3.1.2. Methyl ent-kaur-16-en-19-oate (2). It was obtained from kaurenoic acid (**1**) (500 mg) by usual procedure with an ethereal solution (100 mL) of diazomethane giving the ester **2** (527 mg) in quantitative yield.¹⁰

3.1.3. ent-Kaur-16-en-19-ol (3). LiAlH₄ (146 mg, 3.84 mmol) was added to a solution of methyl ester **2** (135 mg, 0.427 mmol) in dry THF (5 mL). After 3 h reflux, the LiAlH₄ excess was consumed by adding EtOAc (1 mL) and water (10 drops), under external cooling. The mixture was washed with diluted NaOH, concentrated under reduced pressure and submitted to CC, eluting with CH₂Cl₂/AcOEt (9:1) to give **3** (119 mg, 97%), mp 133–135 °C (lit.¹⁰ 134–138 °C). [α]_D²⁵ –72.1° (*c* 1.10, CH₂Cl₂). IR (ν_{\max} /cm^{–1}): 3393, 2922, 2856, 1657, 1440, 1367, 1022, 1005, 878. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+1) Calcd 289.2531. Found: 289.2533.

3.1.4. Methyl-ent-17-hydroxy-16 α -kauran-19-oate (4). The methyl ester **2** (302 mg, 0.956 mmol) in dry THF (20 mL) was treated with diborane generated in situ by adding NaBH₄ (364 mg, 9.62 mmol) followed by BF₃·OEt₂ (dropwise, 1.2 mL, 9.6 mmol). After stirring for 2 h at room temperature under an argon atmosphere, EtOH (10 mL), 5 M NaOH (10 mL) and 30% H₂O₂ (5 mL) were added at 0 °C. Stirring was then continued for 1 h at 50 °C. The THF was evaporated and the residue was dissolved in EtOAc and partitioned with saturated NaCl solution (2× 100 mL). The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure. The recovered product was purified by FCC eluting with *n*-hexane/EtOAc (9:1) to yield **4** (276 mg, 86%). Gum (lit.²⁴ gum), [α]_D²⁵ –68.1° (*c* 0.99, CH₂Cl₂). IR (ν_{\max} /cm^{–1}): 3379, 2983, 2931, 2855, 1726, 1462, 1448, 1375, 1234, 1213, 1192, 1154, 1097, 1032, 1012, 997. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+1) Calcd 335.2586. Found: 335.2588.

3.1.5. 2,3,4,6-Tetra-*O*-acetyl- α -D-glucopyranosyl bromide (5). It was obtained from peracetylated β -D-glucopyranose (1,2,3,4,6-penta-*O*-acetyl- β -D-glucopyranose) (1.01 g, 2.58 mmol) by standard procedure²⁵ to yield **5** (865 mg, 81%).

3.1.6. (2S)-2-Methyl-2-*O*-ent-kaur-16-en-19-yl-(3,4,6-tri-*O*-acetyl-1,2-dideoxy- α -D-glucopyranoso)[2,1-*d*]-1,3-dioxolane (6). A solution of the glucopyranosyl bromide **5** (152 mg, 0.369 mmol) in toluene (5 mL) was added to the kaurene alcohol **3** (85 mg, 0.30 mmol) in dry toluene (15 mL) following addition of Hg(CN)₂ (92 mg, 0.36 mmol). The mixture was kept under a nitrogen atmosphere and was stirred at room temperature for 24 h and then at 80 °C for a further 66 h. The reaction mixture was washed with 5% NaHCO₃ (2× 50 mL) and 10% KI (2× 50 mL), dried (Na₂SO₄) and concentrated under reduced pressure (70 °C). The residue was submitted to FCC eluting with *n*-hexane/EtOAc (9:1) to recuperate **3** (20 mg, 0.07 mmol) and affording the kaurene acetate **7** (19 mg, 25%) and orthoester **6** (62 mg, 44%). Orthoester **6**: colourless oil, [α]_D²⁵ +30.0° (*c* 0.20, CHCl₃). IR (ν_{\max} /cm^{–1}): 2923, 1742, 1657, 1442, 1369, 1384, 1253, 1215, 1117, 1048, 1030, 982, 910, 885. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+1) Calcd 619.3482. Found: 619.3417.

3.1.7. *ent*-Kaur-16-en-19-yl acetate (7). The kaurene acetate **7** was obtained as a white solid, mp 105–107 °C (lit.¹⁰ 104–108 °C). $[\alpha]_D^{25}$ –56.8° (*c* 0.22, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2922, 1732, 1658, 1452, 1442, 1368, 1294, 1237, 1195, 1033, 880. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+1) Calcd 331.2637. Found: 331.2661.

3.1.8. Mixture of *ent*-kaur-16-en-19-yl and *ent*-kaur-15-en-19-yl 2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosides (8a/b). A solution of the glucopyranosyl bromide **5** (680 mg, 1.65 mmol) in toluene (15 mL) was added to the kaurene alcohol **3** (308 mg, 1.07 mmol) in dry toluene (30 mL) and treated with Hg(CN)₂ (450 mg, 1.78 mmol). The mixture was immediately heated at 80 °C and stirred for 140 h, under nitrogen atmosphere. The organic solution was washed with 5% NaHCO₃ (2× 150 mL) and 10% KI (2× 150 mL), dried (Na₂SO₄) and concentrated under reduced pressure (70 °C). The residue was submitted to FCC eluting with *n*-hexane/EtOAc (9:1) to afford the kaurene acetate **7** (175 mg, 50%) and a 1:1 mixture of **8a/b** (223 mg, 34%). Glucosides **8a/b** (1:1): white solid, mp 144–146 °C, $[\alpha]_D^{25}$ –88.9° (*c* 0.18, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2922, 2853, 1747, 1445, 1368, 1229, 1170, 1086, 1066, 1037, 908, 894, 813. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 641.3301. Found: 641.3267.

3.1.9. *ent*-Kaur-16-en-19-yl 2-*O*-acetyl- α -D-glucopyranoside (9). The orthoester **6** (48 mg, 0.08 mmol) in CH₃OH/Et₃N/H₂O (8:1:1) (5 mL) was stirred at room temperature for 24 h. The solution was concentrated under reduced pressure (50 °C) and submitted to FCC eluting with *n*-hexane/EtOAc (1:1) to give **9** as colourless needles (28 mg, 73%), mp 136–137 °C, $[\alpha]_D^{25}$ +7.4° (*c* 0.54, MeOH). IR ($\nu_{\max}/\text{cm}^{-1}$): 3359, 2965, 2923, 1723, 1657, 1439, 1368, 1247, 1150, 1022, 877. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 493.3165. Found: 493.3156.

3.1.10. *ent*-Kaur-16-en-19-yl and *ent*-kaur-15-en-19-yl β -D-glucopyranosides (10a/b). The 1:1 mixture of peracetylated glucosides **8a/b** (205 mg, 0.33 mmol) in dry methanol (8 mL) was treated with sodium methoxide (80 mg, 1.48 mmol) and stirred at room temperature for 4 h. The solution was neutralized with an excess of Amberlite IR 120 (H⁺) resin, filtered and evaporated. The residue was submitted to FCC (EtOAc/MeOH, 8:2), affording a 1:1 mixture of glucosides **10a/b** as colourless needles (139 mg, 93%), mp 193–194 °C, $[\alpha]_D^{25}$ –46.7° (*c* 0.30, MeOH). IR ($\nu_{\max}/\text{cm}^{-1}$): 3345, 2920, 2851, 1657, 1444, 1369, 1270, 1164, 1105, 1073, 1017, 872. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 451.3060. Found 451.3065.

3.1.11. (2*S*)-2-Methyl-2-*O*-*ent*-19-methoxy-19-oxo-16 α -kauran-17-yl-(3,4,6-tri-*O*-acetyl-1,2-dideoxy- α -D-glucopyranosyl)[2,1-*d*]-1,3-dioxolane (11). To the kaurane alcohol **4** (90 mg, 0.27 mmol) in dry toluene (15 mL) was added a solution of the glucopyranosyl bromide **5** (200 mg, 0.486 mmol) in dry toluene (5 mL) and Hg(CN)₂ (130 mg, 0.515 mmol). The mixture was

stirred at room temperature for 24 h, at 60 °C for 48 h and at 80 °C for further 24 h, always under nitrogen atmosphere. The organic solution was washed with 5% NaHCO₃ (2× 50 mL) and 10% KI (2× 50 mL), dried (Na₂SO₄) and concentrated under reduced pressure (70 °C). The residue was submitted to FCC eluting with *n*-hexane/EtOAc (9:1) to recuperate **4** (42 mg, 0.13 mmol) and to afford the orthoester **11** (52 mg, 54%) and the glucopyranoside **12** (29 mg, 30%). Orthoester **11**: colourless oil, $[\alpha]_D^{25}$ +25.0° (*c* 0.16, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2880, 1740, 1725, 1425, 1358, 1215, 1140, 1020, 805. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 687.3351. Found: 687.3419.

3.1.12. *ent*-19-Methoxy-19-oxo-16 α -kauran-17-yl-2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranoside (12). It was yielded as white needles, mp 152–153 °C, $[\alpha]_D^{25}$ –93.8° (*c* 0.32, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2925, 2854, 1752, 1717, 1434, 1368, 1215, 1165, 1151, 1066, 1035, 977, 907. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 687.3351. Found: 687.3327.

3.1.13. *ent*-19-methoxy-19-oxo-16 α -kauran-17-yl 2,3,4,6-tetra-*O*-acetyl- α -D-glucopyranoside (13). The kaurane alcohol **4** (450 mg, 1.35 mmol) in dry toluene (30 mL) was treated with the glucopyranosyl bromide **5** (720 mg, 1.75 mmol) in toluene (15 mL), and Hg(CN)₂ (450 mg, 1.78 mmol). The reaction mixture was heated at 70 °C and stirred for 72 h, under nitrogen atmosphere. The organic solution was washed with 5% NaHCO₃ (2× 150 mL) and 10% KI (2× 150 mL), dried with Na₂SO₄ and concentrated under reduced pressure (70 °C). The residue was submitted to FCC eluting with *n*-hexane/EtOAc (8:2) to afford the kaurane acetate **14** (129 mg, 25%) and the α -glucoside **13** (334 mg, 37%). α -Glucoside **13**: colourless oil, $[\alpha]_D^{25}$ +54.3° (*c* 0.93, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2924, 2857, 1747, 1724, 1436, 1367, 1217, 1149, 1032, 909, 774. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+Na) Calcd 687.3356. Found: 687.3403.

3.1.14. Methyl *ent*-16 α -kauran-17-acetoxy-19-oate (14). The acetate **14** was obtained as a white solid, mp 83–85 °C, $[\alpha]_D^{25}$ –74.8° (*c* 0.53, CHCl₃). IR ($\nu_{\max}/\text{cm}^{-1}$): 2985, 2937, 2858, 1736, 1728, 1464, 1449, 1367, 1237, 1157, 1099, 1033, 973. ¹H NMR data, Table 1. ¹³C NMR data, Table 2. HRMS (FAB-POSI, M+1) Calcd 377.2692. Found: 377.2698.

3.1.15. *ent*-16 α -kauran-19-ol-17-yl α -D-glucopyranoside (15). Peracetylated α -glucoside **13** (90 mg, 0.13 mmol) in dry THF (10 mL) was treated with LiAlH₄ (240 mg, 6.32 mmol) and stirred at room temperature for 1 h. The LiAlH₄ excess was consumed by adding EtOAc (1 mL) and water under external cooling. The mixture was filtered, evaporated under reduced pressure (50 °C) and submitted to FCC (EtOAc/MeOH 8:2) to give α -glucoside **15** as white needles (42 mg, 68%), mp 224–226 °C, $[\alpha]$ +66.7° (*c* 0.24, MeOH). IR ($\nu_{\max}/\text{cm}^{-1}$): 3361, 2916, 2850, 1450,

1356, 1262, 1148, 1111, 1092, 1050, 1007, 855. ^1H NMR data, Table 1. ^{13}C NMR data, Table 2. HRMS (FAB-POSI, $M+1$) Calcd 469.3165. Found: 469.3149.

3.1.16. *ent*-19-methoxy-19-oxo-16 α -kauran-17-yl α -D-glucopyranoside (16). To the peracetylated α -glucoside **13** (91 mg, 0.13 mmol) in dry methanol (10 mL), sodium methoxide (50 mg, 0.93 mmol) was added and the reaction mixture was stirred at room temperature for 4 h. The solution was neutralized with an excess of Amberlite IR 120 (H^+) resin, filtered and evaporated. The residue was submitted to FCC (EtOAc/MeOH 9:1), yielding the α -glucoside **16** as white cubic crystals (52 mg, 81%), mp 92–94 °C, $[\alpha]_{\text{D}}^{25} +48.7^\circ$ (c 0.26, MeOH). IR ($\nu_{\text{max}}/\text{cm}^{-1}$): 3373, 2925, 1725, 1448, 1370, 1235, 1215, 1191, 1148, 1101, 1011, 921, 852, 772. ^1H NMR data, Table 1. ^{13}C NMR data, Table 2. HRMS (FAB-POSI, $M+\text{Na}$) Calcd 497.3114. Found: 497.3123.

3.2. Trypanocidal activity

3.2.1. *In vitro* assay against *T. cruzi* trypomastigotes. Bloodstream forms of *T. cruzi* were obtained from albino mice with established Y strain infections. Blood with a parasite density of 2×10^6 cells/mL was introduced into flat-bottomed test tubes (56 \times 13 mm). Stock solutions of test compounds were prepared by dissolving 0.02 mol of each one in 1% DMSO plus TCM199 (2.0 mL). Aliquots of this solution were mixed with infected blood (0.2 mL) and TCM199 was added to complete the volume of each tube to 0.4 mL to obtain final concentrations of 0.31, 0.63, 1.25, 2.50 and 5.0 mM of each compound. Control tubes with DMSO, DMSO plus TCM199, and gentian violet were run in parallel. All tubes were incubated for 24 h at 4 °C. Thereafter, 5 μL of the suspension was examined microscopically and the parasites counted. The trypanocidal activity was expressed as percentage of parasite number reduction in relation to negative control.²¹

3.2.2. Rapid *in vivo* assay. Adapted from the rapid method originally described by Filardi & Brener.⁸ Swiss male albino mice, 18–20 g, 30 days old, were inoculated intraperitoneally with 5×10^4 blood trypomastigotes of *T. cruzi* Y strain. At the peak of parasitaemia (7th day), a single dose of 250 mg/kg of compounds to be tested, dissolved/suspended in DMSO (0.1 mL) plus LIT (0.9 mL) was given by oral route. Benznidazole (Rochagan[®], Roche; 250 mg/mL in carboxymethylcellulose plus LIT) was the standard drug used as positive control. Untreated mice similarly inoculated were used as controls. The number of circulating trypomastigotes was determined microscopically just before inoculation and then 4 and 6 h after compound administration. The percentage of parasitaemia reduction was calculated by comparing the number of parasites counted at each interval of time after compound administration and pre-treatment. All experiments were undertaken with three mice per group. Means and standard deviations were calculated. The Split-Plot test was used for statistical

analysis. The differences between groups were determined by using Student's *t* test for comparing two groups. Significance was established for $P < 0.05$.

Acknowledgments

We thank UESB (Brazil) for supporting R.B. with a Ph.D. fellowship; CNPq (Brazil) for research fellowships to A.B.O. and E.C.; Arturo San Feliciano, University of Salamanca, Spain, for MS spectra; and Ivan Barbosa Machado Sampaio, Federal University of Minas Gerais, for statistical assistance. Technical assistance by Afonso da Costa Viana/ICB/UFMG, for the biological assays, is fully acknowledged.

References and notes

1. Urbina, J. A.; Docampo, R. *Trends Parasitol.* **2003**, *19*, 495.
2. Coura, J. R.; De Castro, S. L. *Mem. Inst. Oswaldo Cruz* **2002**, *97*, 3.
3. WHO—World Health Organization, Control of Chagas' Disease; *Tech. Rep. Ser.* 2002, 905, pp 1–109.
4. Kirchhoff, V. L. In *Emerging Infections*; Scheld, W. M. et al., Eds.; ASM Press, 1999; pp 111–134.
5. Wendel, S.; Dias, J. C. P. In *Chagas' Disease (American Trypanosomiasis): Its Impact On Transfusion and Clinical Medicine* Wendel, S., Brener, Z., Camargo, M. E., Rassi, A., Eds.; ISBT Brazil'92-SBHHSch: São Paulo, 1992; p 165.
6. Chiari, E.; Oliveira, A. B.; Prado, M. A. F.; Alves, R. J.; Galvão, L. M. C.; Araujo, F. G. *Antimicrob. Agents Chemother.* **1996**, *40*, 613.
7. Moraes-Souza, H.; Pianetti, G. M.; Pereira-Barreto, C.; Nonoyama, K.; Grogl, M.; Chiari, E. *Rev. Soc. Bras. Med. Trop.* **2002**, *35*, 563.
8. Filardi, L. S.; Brener, Z. *Mem. Inst. Oswaldo Cruz* **1984**, *2*, 221.
9. Alves, T. M. A.; Chaves, P. P. G.; Santos, L. M. S. T.; Nagem, T. J.; Murta, S. M. F.; Ceravolo, I. P.; Romanha, A. J.; Zani, C. L. *Planta Med.* **1995**, *61*, 85.
10. Costa, F. B.; Albuquerque, S.; Vichnevski, W. *Planta Med.* **1996**, *62*, 557.
11. Batista, R.; Chiari, E.; Oliveira, A. B. *Planta Med.* **1999**, *65*, 283.
12. Leite, J. P. V.; Lombardi, J. A.; Chiari, E.; Oliveira, A. B. *Rev. Bras. Farmacogn.* **2001**, *11*, 77.
13. Cunha, W. R.; Martins, C.; Ferreira, D. S.; Crotti, A. E.; Lopes, N. P.; Albuquerque, S. *Planta Med.* **2003**, *69*, 470.
14. Leite, J. P. V.; Oliveira, A. B.; Lombardi, J. A.; Souza Filho, J. D.; Chiari, E. *Biol. Pharm. Bull.*, **2006**, in press.
15. Vieira, H. S.; Takahashi, J. A.; Oliveira, A. B.; Chiari, E.; Boaventura, M. A. D. *J. Braz. Chem. Soc.* **2002**, *13*, 151.
16. Batista, R.; Braga, F. C.; Oliveira, A. B. *Rev. Bras. Farmacogn.* **2005**, *15*, 119.
17. Vieira, H. S.; Takahashi, J. A.; Boaventura, M. A. D. *App. Microbiol. Biotechnol.* **2000**, *53*, 601.
18. Lubineau, A.; Gallic, J.; Lemoine, R. *J. Chem. Soc. Chem. Commun.* **1993**, *111*, 1419.
19. Roode, B. M.; Franssen, M. C. R.; Van der Padt, A.; Boom, R. M. *Biotechnol. Prog.* **2003**, *19*, 1391.
20. Nukada, T.; Berges, A.; Zgierski, M. Z.; Whitefield, D. M. *J. Am. Chem. Soc.* **1998**, *120*, 13291.

21. Chiari, E.; Duarte, D. S.; Raslan, D. S.; Saúde, D. A.; Perry, K. S. P.; Boaventura, M. A. D.; Grandi, T. S. M.; Stehmann, J. R.; Anjos, A. M. G.; Oliveira, A. B. *Phytoter. Res.* **1996**, *10*, 636.
22. Faria, T. J.; Silva, L. G. F.; Souza-Filho, J. D.; Chiari, E.; Oliveira, A. B. *J. Braz. Chem. Soc.* **2005**, *16*, 1415.
23. Kren, V.; Martinková, L. *Curr. Med. Chem.* **2001**, *8*, 1303.
24. Etse, J. T.; Gray, A. I.; Waterman, P. G. *J. Nat. Prod.* **1987**, *50*, 979.
25. Iwakura, Y.; Imai, Y.; Yagi, K. *J. Polym. Sci., Part A-1: Polym. Chem.* **1968**, *6*, 1625.